Dr. Ze-Mao Gong,
Science Editor, Editorial Office
Baishideng Publishing Group Inc.

Re: Name of journal: World Journal of Gastroenterology
Manuscript NO.: 31467
Column: Basic Study
Title: Naringenin prevents experimental liver fibrosis by blocking TGFβ-Smad3 and JNK-Smad3 pathways
Authors: Erika Hernández-Aquino, Natanael Zarco, Sael Casas-Grajales, Erika Ramos-Tovar, Rosa E Flores-Beltrán, Jonathan Arauz, Mineko Shibayama, Liliana Favari, Víctor Tsutsumi, José Segovia and Pablo Muriel
Correspondence to: Dr. Pablo Muriel Laboratory of Experimental Hepatology Department of Pharmacology CINVESTAV-IPN Av. Instituto Politécnico Nacional 2508 Col. San Pedro Zacatenco, 07360 Apartado postal 14-740, 07000 México City. MÉXICO Mail: pmuriel@cinvestav.mx Phone: (52-55) 5747-3303 Fax: (52-55) 5747-3394
Reviewer code: 03576374 and 00742516
First decision: 2017-03-03 09:00
Scientific editor: Ze-Mao Gong

Dear Dr. Gong,

I chose to revise the manuscript and thus I am answering your mail:

STEP 1. PLEASE REVISE YOUR MANUSCRIPT ACCORDING TO THE REVIEWERS' COMMENTS.

Reviewer 00742516 said: "In this study, authors have shown that the molecular mechanisms involved in the hepatoprotective effects of naringenin (NAR) on carbon tetrachloride (CCl4) induced liver fibrosis. NAR prevents CCl4 induced liver inflammation, necrosis and fibrosis, due to its antioxidant capacity as free radical inhibitor and by inhibiting the NF-κB, TGF-β-Smad3 and JNK-Smad3 pathways. So NAR may be utilized in human fibrosis previous clinical and toxicological evaluation. Technically, this approach is very interesting. The experiment design is reasonable, the figures are clear and the evidence is sufficient. This article complies with published requirements of the magazine." The reviewer rated the manuscript as follows: **Classification Grade B (Very good), Language evaluation Grade A: priority publishing, Conclusion Accept.**

Answer:

We appreciate the favorable comments and the result of the evaluation of reviewer.

Reviewer 31467 said: In this study, authors have shown that the molecular mechanisms involved in the hepatoprotective effects of naringenin (NAR) on carbon tetrachloride (CCl4) induced liver fibrosis. NAR prevents CCl4 induced liver inflammation, necrosis and fibrosis, due to its antioxidant capacity as free radical inhibitor and by inhibiting the NF-κB, TGF-β-Smad3 and JNK-Smad3 pathways. So NAR may be utilized in human fibrosis previous clinical and toxicological evaluation. Technically, this approach is very interesting. The experiment design is reasonable, the figures are clear and the evidence is sufficient. This article complies with published requirements of the magazine. The reviewer rated the manuscript as follows: **Classification Grade B (Very good), Language evaluation Grade A: priority publishing, Conclusion Accept.**

Answer:
We appreciate the favorable comments and the result of the evaluation of the reviewer.

Reviewer 03576374 said: The paper by Hernández-Aquino et al investigated the hepato-protective and anti-fibrotic effects of naringenin (NAR) using a carbon-tetrachloride (CCl4)-induced liver fibrosis model. The authors found NAR protects liver functions in the CCl4-treated livers, and reduces levels of oxidative stress, fibrosis, and inflammation. This is an interesting paper which has implications for possible mechanisms underlying hepato-protective and anti-fibrotic effects of NAR. The manuscript was well written and the data support their claims. No further requests are required. The reviewer rated the manuscript as follows: **Classification Grade B (good), Language evaluation Grade A: priority publishing, Conclusion Accept**

Answer:
We appreciate the favorable comments and the result of the evaluation of the reviewer.

Editor Suggestions in the manuscript file:

1. **You'd better offer us one paper with word format next (such as, .doc or .docx), which is easy to be edited and helpful to accept earlier. Thank you very much!**

Answer:
This was done.

2. **Please provide language certificate letter by editing companies (Classification of manuscript language quality evaluation is B). For manuscripts submitted by non-native speakers of English, please provided language certificate by professional English language editing companies mentioned in 'The Revision Policies of BPG for Article'.**

Answer:
This was done. Please see the attached certificate.

3. **Please provide one report:**
   Scientific Research Process
   Name of Journal: World Journal of Gastroenterology
   ESPS Manuscript NO:
   Manuscript Type: ORIGINAL ARTICLE
   Title:
   Authors:
   Correspondence to:

   1 What did this study explore?
   2 How did the authors perform all experiments?
   3 How did the authors process all experimental data?
   4 How did the authors deal with the pre-study hypothesis

5 What are the novel findings of this study?

At last, sign (handwrite) your name in the end of file.

Answer:
This was done. Please see new version of the manuscript.

4. **Please revise and perfect your manuscript according to peer-reviewers' comments.**

Answer:
This was done. Please see new version of the manuscript. Changes are highlighted in yellow.

5. **add postcode**

Answer:
This was done. Please see new version of the manuscript. Changes are highlighted in yellow.

6. **Institutional review board statement:**
   Informed consent statement:
   Institutional animal care and use committee statement:
   Animal care and use statement:
   Biostatistics statement:
   Conflict-of-interest statement:
   Data sharing statement:

Answer:
This was done. Please see new version of the manuscript. Changes are highlighted in yellow.

7. **Audio core tip:**
   In order to attract readers to read your full-text article, we request that the author make an audio file describing your final core tip, it is necessary for final acceptance. Please refer to Instruction to authors on our website or attached Format for detailed information.
   Please provide all authors abbreviation names and manuscript title here.
   World J Gastroenterol 2017; In press

Answer:
This was done. Please see new version of the manuscript. Changes are highlighted in yellow. An Audio core tip as uploaded.

8. **Please check that there are no repeated references!**

Answer:
This was done. Referenced were updated.

9. **Please provide the decomposable figure of Figures, whose parts are movable and editable. So please put the original picture as ppt so that we can edit them easily.**

Answer:

This was done. Figures uploaded as a PPT file to facilitated edition.